A monoclonal antibody against a CEA-related antigen expressed on HT29 colon tumour cells

Rogers, G. T.; Rawlins, G.A.; Kardana, Andrew; Gibbons, Anthea; Bagshawe, K. D.

doi:10.1016/0277-5379(84)90257-8

Cited by 4 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The monoclonal antibody A5B7 used in this study has been described previously (Rogers et al, 1984) and has been used preclinically and clinically for the RIT of CEA-expressing tumours (Begent et al, 1989;Pedley et al, 1991Pedley et al, , 1993Pedley et al, , 1994Pedley et al, , 2001Lane et al, 1994). The antibody was radiolabelled on day 1 using the chloramine-T method (Greenwood and Hunter, 1963) at a ratio of 5 MBq 131 I to 1 mg antibody and sterilised by passage through a 0.22 mm acrodisc filter.…”

Section: Antibody and Radiolabelingmentioning

confidence: 99%

Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice

et al. 2008

View full text Add to dashboard Cite

Dose fractionation has been proposed as a method to improve the therapeutic ratio of radioimmunotherapy (RIT). This study compared a single administration of 7.4 MBq 131 I-anti-CEA antibody given on day 1 with the same total activity given as fractionated treatment: 3.7 MBq (days 1 and 3), 2.4 MBq (days 1, 3, and 5) or 1.8 MBq (days 1, 3, 5, and 8). Studies in nude mice, bearing the human colorectal xenograft LS174T, showed that increasing the fractionation significantly reduced the efficacy of therapy. Fractionation was associated with a decrease in systemic toxicity as assessed by weight, but did not lead to any significant decrease in acute haematological toxicity. Similarly, no significant decrease in marrow toxicity, as assessed by colony-forming unit assays for granulocytes and macrophages (CFU gm ), was seen. However, there was a significant depression of CFU gm counts when all treated animals were compared with untreated controls, suggesting that treatment did suppress marrow function. In conclusion, in this tumour model system, fractionated RIT causes less systemic toxicity, but is also less effective at treating tumours.

show abstract

Section: Antibody and Radiolabelingmentioning

confidence: 99%

Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Monoclonal antibodies MA/200 and H58 were raised against purified CEA and HT29 colon tumour cells respectively as previously described (Rogers et al, 1983;Rogers et al, 1984). The remaining 13 MAbs (Table I) were raised against heat-treated CEA using the following procedure.…”

Section: Immunisation Schedulementioning

confidence: 99%

“…Spleen cells from the immunised mice were then fused with either SP2/0-Ag 14 or P3-NS/1-Ag4-1 myeloma cells (Flow Laboratories, UK) as previously described (Rogers et al, 1984) Affinity constants were determined from inhibition data by the method of Scatchard as previously described (Rogers et al, 1983 On the basis of epitope analysis alone, it was concluded that at least six unrelated regions of the CEA glycoprotein were capable of reacting with different groups of monoclonal antibodies ( Figure 3). …”

Section: Immunisation Schedulementioning

confidence: 99%